Radium Ra 223 dichloride
- Generic Name
- Radium Ra 223 dichloride
- Brand Names
- Xofigo
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2Ra
- CAS Number
- 444811-40-9
- Unique Ingredient Identifier
- RJ00KV3VTG
- Background
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is cur...
- Indication
Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT02346526
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 49
- Registration Number
- NCT02199197
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.